Totaligent, Inc. 8-K

What Happened

• Totaligent, Inc. filed an 8-K on March 24, 2026 reporting that on March 4, 2026 it entered an Extension Amendment to the Binding Letter of Intent (LOI) dated February 11, 2026 with Aetherium Medical.
• The LOI covers a proposed acqui-hire under which Totaligent would acquire Aetherium’s team, business plan, intellectual property, know‑how, contacts and related assets in exchange for equity in Totaligent.
• The Amendment pushes the target dates for negotiation/execution of definitive agreements and the target closing date from March 5, 2026 to April 10, 2026; the binding exclusivity period in the LOI remains in effect through April 10, 2026 (or earlier as provided in the LOI). The Amendment is filed as Exhibit 10.1 to the 8-K.

Key Details

• LOI originally dated: February 11, 2026.
• Amendment entered: March 4, 2026; 8-K filed: March 24, 2026.
• Original target closing/negotiation date: March 5, 2026 → extended to April 10, 2026.
• Exclusivity period: extended through April 10, 2026 (subject to LOI terms).

Why It Matters

• For investors, the filing confirms the acqui-hire deal is still being negotiated but will not close by the original March 5 target; negotiations and due diligence now continue through at least April 10, 2026.
• The transaction contemplates equity consideration, so any future closing could affect outstanding share count and ownership, and timing has been delayed until definitive agreements are completed.
• The maintained exclusivity means Totaligent currently has sole negotiation rights under the LOI through April 10, 2026, reducing the risk of competing bids during that period.